IP Verse

Dry Powder Formulations For Inhalation - EP3107548

The patent EP3107548 was granted to Otitopic on Jul 20, 2022. The application was originally filed on Feb 20, 2015 under application number EP15752250A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3107548

OTITOPIC
Application Number
EP15752250A
Filing Date
Feb 20, 2015
Status
Opposition Rejected
Sep 19, 2024
Grant Date
Jul 20, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKMar 8, 2023ELKINGTON AND FIFEADMISSIBLE

Patent Citations (35) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0217609
DESCRIPTIONUS2006249144
DESCRIPTIONUS2009208582
DESCRIPTIONUS4069819
DESCRIPTIONUS4995385
DESCRIPTIONUS5511726
DESCRIPTIONUS5551416
DESCRIPTIONUS5724957
DESCRIPTIONUS5855913
DESCRIPTIONUS5874064
DESCRIPTIONUS5993805
DESCRIPTIONUS6098620
DESCRIPTIONUS6131570
DESCRIPTIONUS6136295
DESCRIPTIONUS6546928
DESCRIPTIONUS6582729
DESCRIPTIONUS6737044
DESCRIPTIONUS7182961
DESCRIPTIONUS7601336
DESCRIPTIONUS8614255
DESCRIPTIONUS9216527
DESCRIPTIONWO0000176
DESCRIPTIONWO0000215
DESCRIPTIONWO9916419
INTERNATIONAL-SEARCH-REPORTUS2008306033
INTERNATIONAL-SEARCH-REPORTUS2010258118
INTERNATIONAL-SEARCH-REPORTUS2014322328
INTERNATIONAL-SEARCH-REPORTUS6979437
OPPOSITIONUS2008044481
OPPOSITIONUS2008306033
OPPOSITIONUS2010258118
OPPOSITIONUS2014322328
OPPOSITIONUS6979437
OPPOSITIONWO2014178891
SEARCHUS2008044481

Non-Patent Literature (NPL) Citations (11) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
EXAMINATION- H.J.M. BARNETT; M. KASTE; H.MELDRUM; M. ELIASZIW, "Aspirin dose in stroke prevention", STROKE, (19961231), vol. 27, doi:10.1161/01.STR.27.4.588, pages 588 - 592, XP093087061
OPPOSITION- R. VEHRING, "Pharmaceutical Particle Engineering via Spray Drying", Pharmaceutical Research, (20070000), vol. 25, no. 5, pages 999 - 1022, XP019613056
OPPOSITION- SOLETI et al., "Aspirin inhalation treatment for COPD patients: Preliminary studies on PK and inflammatory biomarkers", European Respiratory Journal, (20110925), vol. 38, no. S55, pages 138S - 138S
OPPOSITION- Taylor K., "Pulmonary drug delivery", Taylor K., Michael E. Aulton, Pharmaceutics The Science of Dosage Form Design, UK, CHURCHILL LIVINGSTONE, (20020000), pages 473 - 487, chapter 31, XP93087065
OPPOSITION- Zeng Xian Ming,, Gary P, Marriott Christopher, "3.6 PHYSICO-CHEMICAL PROPERTIES OF DRUG PARTICLES", Particulate Interactions in Dry Powder Formulations for Inhalation, Taylor & Francis, (20010101), pages 86 - 88, XP093137142
OPPOSITION- Nathalie Wauthoz; Karim Amighi, "Phospholipids in pulmonary drug delivery", European Journal of Lipid Science Technology, WILEY VCH VERLAG, WEINHEIM., DE, DE , (20140605), vol. 116, no. 9, doi:10.1002/ejlt.201300368, ISSN 1438-7697, pages 1114 - 1128, XP072145719
OPPOSITION- Gabrielle Pilcer ; Thami Sebti ; Karim Amighi, "Formulation and Characterization of Lipid-Coated Tobramycin Particles for Dry Powder Inhalation", Pharmaceutical Research, Kluwer Academic Publishers-Plenum Publishers, NL, NL , (20060502), vol. 23, no. 5, doi:10.1007/s11095-006-9789-4, ISSN 1573-904X, pages 931 - 940, XP019405247
OPPOSITION- K. HADINOTO et al., "Drug release study of large hollow nanoparticulate aggregates ''carrier particles for pulmonary delivery", International Journal of Pharmaceutics, (20070000), vol. 341, doi:10.1016/j.ijpharm.2007.03.035, pages 195 - 206, XP022166304
OPPOSITION- Bhatt D.L., Fox K.A., Hacke W., Berger P.B., Black H.R., Boden W.E., Cacoub P., Cohen E.A., Creager M.A., Easton J.D., Flather M.D., Haffner S.M., Hamm C.W., Hankey G.J., Johnston S.C., Mak K.H., Mas J.L., Montalescot G., Pearson T.A., Steg P.G., Steinhubl S.R., Weber M.A., Brennan D.M., Fabry-Ribaudo L., Booth J., Topol E.J., "Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events", The NEW ENGLAND JOURNAL of MEDICINE, Chicago, Chicago, (20060420), vol. 354, no. 16, pages 1706 - 1717, XP093087070
OPPOSITION- Barnett H.J.M., Kaste M., Meldrum H., Eliasziw M., "Aspirin Dose in Stroke Prevention : Beautiful Hypotheses Slain by Ugly Facts", STROKE, Lippincott Williams & Wilkins, US, US , (19960401), vol. 27, no. 4, doi:10.1161/01.STR.27.4.588, ISSN 0039-2499, pages 588 - 592, XP093087061
SEARCH- HADINOTO ET AL, "Drug release study of large hollow nanoparticulate aggregates carrier particles for pulmonary delivery", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, AMSTERDAM, NL, (20070724), vol. 341, no. 1-2, doi:10.1016/J.IJPHARM.2007.03.035, ISSN 0378-5173, pages 195 - 206, XP022166304 [A] 1-15 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents